Metabasis Therapeutics (NASDAQ:MBRX) to Hold Q4 2007 Earnings Conference Call March 17

Metabasis Therapeutics (NASDAQ:MBRX) will hold a hold a conference call on Monday, March 17 at 4:30 pm to discuss the fourth quarter earnings for 2007.

Metabasis Therapeutics, a biopharmaceutical company, is focused on the discovery, development and commercialization of drugs for the liver and liver pathways.  CS-917, MB07803, MB07811, Pradefovir and MB07133 are the company’s five product candidates in clinical trials.

CS-917 is intended to treat type 2 diabetes and is in Phase II clinical trials.

MB07803 is to manage hyperlipdemia and reduce elevated cholesterol levels and triglycerides.

Pradefovir is to treat hepatitis B has finished Phase II of the clinical trials.

MB07133 is a candidate to treat primary liver cancer and has completed both Phase I and Phase II of the clinical trial.

For more Conference Call related events or to post your own events, visit:

http://events.finditt.com/Events_List.aspx?catid=12